Cannabis Use, Neurobiology, Psychology, and Treatment
- 1st Edition - June 2, 2023
- Editors: Colin R Martin, Vinood B. Patel, Victor R Preedy
- Language: English
- Hardback ISBN:9 7 8 - 0 - 3 2 3 - 8 9 8 6 2 - 1
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 9 0 1 4 0 - 6
Cannabis Use, Neurobiology, Psychology, and Treatment offers readers a comprehensive reference on neurological changes, both transient and long-term, and other factors surrou… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteCannabis Use, Neurobiology, Psychology, and Treatment offers readers a comprehensive reference on neurological changes, both transient and long-term, and other factors surrounding the use of these compounds and extracts. With coverage of both natural and synthetic cannabinoids, this broad coverage allows readers to learn about both adverse and non-adverse effects, including reactivity to pain, changes in behavior, and neuroactivity. This volume provides a platform for research on the effects of these compounds in brain function and neurological dysfunction. Extracts from the Cannabis sativa plant contain scores of psychoactive compounds in addition to the principal agent tetrahydrocannabinol, many of which are neuroactive.
- Summarizes cannabis and cannabinoid research in relation to neurological function
- Contains chapter abstracts, key facts, a dictionary and a summary
- Covers the neuroactivity of multiple Cannabis compounds beyond tetrahydrocannabinol
- Includes conditions like depression, anxiety, Parkinson’s, psychosis, and epilepsy
- Discusses brain structure and brain development, including functional connectivity
Researchers in neuroscience and the biomedical sciences, behavioral neuroscientists
- Cover image
- Title page
- Table of Contents
- Copyright
- Dedication
- Contributors
- Preface
- Part I: Setting the scene and introductory chapters
- Chapter 1: Metabolomics of the cannabis plant
- Abstract
- Introduction
- Analytical tools and methods for metabolomics studies in cannabis
- Understanding cannabis through metabolomics
- The future of cannabis metabolomics
- Concluding remarks
- Applications to other areas
- Key facts
- Mini-dictionary of terms
- Summary points
- References
- Chapter 2: Cannabis sativa roots: Chemical and pharmacological profile
- Abstract
- Introduction
- Chemical aspects of Cannabis sativa roots
- Toxicological aspects of Cannabis sativa roots
- Pharmacological aspects of Cannabis sativa roots
- Mini-dictionary of terms
- Key facts of marijuana roots
- Summary points
- References
- Chapter 3: Cannabis-related compounds in beverages and food
- Abstract
- Introduction
- Analytical methods for determination of cannabinoids in dietary products
- Cannabinoid determination in hemp-derived ingredients
- Cannabinoids monitoring in food and beverages containing hemp-derived ingredients
- Cannabinoids content in cereals, cereal-derived, and bakery products
- Cannabinoids content in products for infusion and animal-derived products
- Cannabinoids content in alcoholic and nonalcoholic beverages
- Cannabinoids content in other dietary products
- Conclusions
- Applications to other areas
- Mini-dictionary of terms
- Summary points
- References
- Chapter 4: The impact of prenatal cannabis exposure: An overview
- Abstract
- Introduction
- Current state of PCE research
- Summary
- Applications to other areas
- Key facts of PCE
- Mini-dictionary of terms
- Summary points
- References
- Chapter 5: Cannabinoid genotoxicity and congenital anomalies: A convergent synthesis of European and USA data sets
- Abstract
- Introduction
- Methodologies
- Analyses
- Consideration of analyses
- Specific congenital anomalies of interest
- Conclusion
- Applications to other areas
- Mini-dictionary of terms
- Key facts of cannabinoid teratogenesis
- Summary points
- References
- Chapter 6: Cannabis genotoxicity and cancer incidence_ Highly concordant synthesis of European and USA datasets
- Abstract
- Introduction
- Triple confluence of recent cannabis trends
- Exponential cannabinoid genotoxicity dose-response curves
- Modern epigenomic insights
- Methodological considerations
- Comparative analyses
- Consideration of findings
- Acute myeloid leukemia
- Acute lymphoid leukemia
- Biological mechanisms
- Cannabinoid-induced chromosomal pathophysiology
- Cannabinoid-induced disruption of mitochondria: Epigenome interactions
- Cannabinoid-induced epigenomic disruption of cancer-related genes
- Cannabinoid-induced disruption of chromatin looping
- Exponentiation of cannabinoid-related genotoxicity
- Qualitative causal inference
- Quantitative causal inference
- Generalizability
- Strengths and limitations
- Conclusion
- Applications to other areas
- Mini-dictionary of terms
- Key facts of cannabinoid cancerogenicity
- Summary points
- References
- Chapter 7: Cannabis, cognitive impairment and car crash risk
- Abstract
- Introduction
- Cannabis-induced impairments: Results from lab and simulation studies
- Meta-analyses: Cannabis-induced cognitive changes and crash risks
- Discussion
- Summary
- Applications to other areas
- Key facts
- Summary points
- References
- Part II: Cannabis usage
- Chapter 8: Recreational cannabis use: French perspective of adverse effects
- Abstract
- Introduction
- Addictovigilance in France
- Rates of cannabis use in France
- Adverse effects of recreational cannabis use in France
- Perspectives
- Conclusion
- Mini-dictionary of terms
- Key facts of recreational cannabis use: French perspective of adverse effects
- Summary points
- References
- Chapter 9: Acute and chronic impact of cannabis on human cognition
- Abstract
- Introduction
- Mechanisms of cannabis-induced cognitive impairment
- Methods for studying cognitive effects of cannabis in humans
- Effects of cannabis and cannabinoids on human cognition
- Factors influencing the cognitive effects of cannabis and cannabinoids
- Application to other areas
- Mini-dictionary of terms
- Key facts of testing cognitive functions
- Summary points
- References
- Chapter 10: Polydrug users, use of cannabinoids and abuse potential: A focus on cannabidiol (CBD)
- Abstract
- Introduction
- Abuse and dependence potential of CBD in animals
- Abuse and dependence potential of CBD in humans
- Evidence of CBD abuse in polydrug users
- Misuse of CBD products
- Use of CBD in treatment of substance-use disorders
- Conclusions
- Applications to other areas
- Mini-dictionary of terms
- Key facts of CBD abuse potential
- Summary points
- References
- Chapter 11: Cannabis stigmas: A narrative of features
- Abstract
- Introduction
- Main text
- Applications to other areas
- Mini-dictionary of terms
- Key facts of cannabis stigmas
- Summary points
- References
- Chapter 12: Alterations of THC and CBD ratios and impact on cognition
- Abstract
- Introduction
- Effect of different THC:CBD ratio on human cognition
- Effect of different THC:CBD ratio on cognition: Preclinical evidence
- Conclusions
- Applications to other areas
- Key facts of THC
- Key facts of CBD
- Mini-dictionary of terms
- Summary points
- References
- Chapter 13: When cannabis is used for medicinal purposes: A focus on back pain
- Abstract
- Introduction
- Types of back pain
- Multifactorial back pain
- Opiate use for back pain
- Pain management in the United States
- Contrast with global pain management
- Legality of cannabis worldwide
- Acceptance of cannabis for medicinal purposes
- Cannabis mechanism of action
- Review of evidence
- Cannabis reduces opiate use
- Adverse events
- Conclusion
- Reducing opiate use
- Forthcoming research
- Applications to other areas
- Mini-dictionary of terms
- Key facts of opioid addiction
- Summary points
- References
- Part III: Pharmacological and physiological aspects
- Chapter 14: Cannabis, cannabinoids, and receptor responses
- Abstract
- Introduction
- C5 cannabinoids
- C3 cannabinoids
- Applications to other areas: Deconvoluting the chemical complexity of medical cannabis
- Key facts of cannabinoid receptors
- Mini-dictionary of terms
- Summary points
- References
- Chapter 15: Cannabidiol (CBD): Abuse and physical dependence potential
- Abstract
- Introduction
- Preclinical abuse potential evaluation of CBD
- Clinical abuse potential evaluation of CBD
- Physical dependence potential of CBD
- Applications to other areas
- Mini-dictionary of terms
- Key facts of CBD
- Summary points
- References
- Chapter 16: 4,5-Dihydro-1H-pyrazole/3,4-Diarylpyrazoline class of cannabinoid-1 (CB1R) receptor antagonists and their potential in medicinal applications
- Abstract
- Introduction
- Targeting the ECS CB1R with brain-penetrant CB1 blockers
- Peripherally-restricted (PR) CB1R blockers
- Designing PR CB1 blockers
- Chemistry of 4,5-1H-dihydropyrazole (3,4-diarylpyrazoline) scaffold-based CB1 antagonists
- General synthesis schemes for dihydropyrazoline-type compounds
- Computational models
- Application to other areas and summary
- Mini-dictionary of terms
- Key facts of 3,4-diarylpyrazolines CB1R modulators
- Summary points
- References
- Part IV: Neurobiology of cannabis
- Chapter 17: Neurobiology of the endocannabinoid system and relevance to cannabis use
- Abstract
- Introduction
- Endocannabinoid system
- Physiological outcomes of endocannabinoids
- Evidence of endocannabinoids in neuropathology (Fig. 1B)
- Conclusion
- Summary points
- References
- Chapter 18: Neurobiology of the kynurenine pathway and cannabis misuse: A new narrative
- Abstract
- Introduction
- The kynurenine pathway
- Targets of kynurenine pathway metabolites
- Interaction of cannabinoids with the kynurenine pathway targets
- Interaction of kynurenine pathway metabolites with CBR
- Animal studies on the effects of cannabinoids on the kynurenine pathway
- Humans
- Effects of modulation of the kynurenine pathway on cannabis misuse
- Applications to other areas
- Key facts of the kynurenine pathway
- Mini-dictionary of terms
- Summary points
- References
- Chapter 19: Central nervous system cancers and use of cannabis and related products: An updated narrative
- Abstract
- Overview
- Global incidence, prevalence, and survival of gliomas
- Classification of gliomas
- Glioma risks factors
- Treatment and management of gliomas
- Cannabinoids and gliomas
- Antitumoral action of cannabinoids in glioma cells
- Potential therapeutic applications of cannabinoids in gliomas
- Clinical experience of cannabis in gliomas
- Side effect management
- Clinical trials
- Applications to other areas
- Mini-dictionary of terms
- Key facts of central nervous system cancers and use of cannabis and related products
- Summary points
- References
- Chapter 20: The relationship between glutamate and resting-state connectivity in chronic cannabis users
- Abstract
- Introduction
- Glutamate and addiction
- Glutamate and cannabis
- Resting-state connectivity and cannabis
- Glutamate and resting-state connectivity
- Cannabis, glutamate, and resting-state connectivity
- Implications
- Applications to other areas
- Mini-dictionary of terms
- Key facts of resting-state functional connectivity
- Key facts of glutamate
- Summary points
- References
- Chapter 21: Brain metabolic responses to cannabis use in people with multiple sclerosis: Insights from [18F]-FDG positron emission tomography and functional MRI
- Abstract
- Cannabis
- Multiple sclerosis
- In vivo neuroimaging
- PET, cannabis, and MS
- fMRI, cannabis, and MS
- Conclusion
- Applications to other areas
- Mini-dictionary of terms
- Key facts of neuroimaging
- Summary points
- References
- Chapter 22: Genetic variation and acute responses to cannabis
- Abstract
- Conflict of interest statement
- Introduction
- Genetics of the endocannabinoid system
- Behavioral pharmacology of cannabinoids
- Experimental measures
- Genetic polymorphisms involved in acute responses to cannabis
- Applications to other areas
- Mini-dictionary of terms
- Key facts of candidate gene association studies
- Summary points
- References
- Chapter 23: Cell signaling of the CB1 cannabinoid receptor via β-arrestins, cannabinoid receptor interacting protein (CRIP1a) and other regulatory proteins
- Abstract
- Introduction
- Proteins that regulate signal transduction pathways
- Cannabinoid receptor signaling through β-arrestins
- Cannabinoid receptor interacting protein 1a (CRIP1a) and CB1Rs
- Proteins that regulate CB1R trafficking
- Wntless (WLS/GPR177) as CB1R- and CB2R-interacting proteins
- G protein receptor-associated sorting protein 1 (GASP1) and CB1R lysosomal degradation
- Conclusions
- Key facts
- Mini-dictionary of terms
- Summary points
- References
- Chapter 24: Impact of cannabis on memory: From in utero to adulthood
- Abstract
- Introduction
- Prenatal cannabis exposure and memory
- Adolescent cannabis use and memory
- Adult cannabis use and memory
- Effects of cannabis on memory across the lifespan
- Polydrug use
- Compensatory brain function
- Methodological limitations
- Concluding remarks
- Applications to other areas
- Mini-dictionary of terms
- Key facts of the impact of cannabis on memory: From in utero to adulthood
- Summary points
- References
- Chapter 25: Age-related considerations in the use of cannabinoids: Focus on drug interactions, physiology, and drug effects
- Abstract
- Introduction
- Uses of cannabis
- Geriatric special considerations
- Age-related CB1 receptor expression variation
- Age-related CB1 receptor function variation
- Age-related cannabinoids behavioral effect variation
- Conclusion
- Applications to other areas
- Mini-dictionary of terms
- Key facts of drug-drug interaction
- Key facts of cannabinoid receptor function and expression
- Summary points
- References
- Further reading
- Chapter 26: Cannabis, binge drinking, and memory in adolescents and young adults
- Abstract
- Introduction
- Effects of cannabis on memory (in healthy adolescents with recreational use)
- Effects of binge drinking on memory
- Effects of polydrug use (cannabis + alcohol BD) on memory
- Conclusions
- Applications to other areas
- Mini-dictionary of terms
- Key facts of cannabis, binge drinking, and memory in adolescents and young adults
- Summary points
- References
- Part V: Neurobiology of cannabinoids
- Chapter 27: The role of ΔFosB in the plasticity of the cannabinoid system
- Abstract
- Introduction
- Cannabis and cannabinoids
- Endocannabinoids
- ΔFOSB
- Interaction
- Conclusion
- Applications to other areas
- Key facts
- Mini-dictionary of terms
- Summary points
- References
- Chapter 28: Functional profile of synthetic cannabinoid receptor agonists: Exploring cannabinoid and noncannabinoid targets
- Abstract
- Introduction
- Molecular targets of synthetic cannabinoid receptor agonists (SCRAs)
- Ion channels
- Conclusion
- Applications to other areas
- Mini-dictionary of terms
- Key facts of functional profile of synthetic cannabinoid receptor agonists: Exploring cannabinoid and noncannabinoid targets
- Summary points
- References
- Chapter 29: Linking the G-protein-coupled receptor 55 (GPR55) to the cannabinoid receptors (CB1 and CB2): A new narrative
- Abstract
- Introduction
- The endocannabinoid system
- Endocannabinoids (ECs) biosynthesis and metabolism
- Cannabinoid receptors CB1 and CB2
- Linking GPR55
- Considerations on GPR55 as a potential therapeutic target: Pathophysiologic and toxicologic issues
- Brain reward system and destructive behaviors
- Conclusions
- Applications to other areas
- Mini-dictionary of terms
- Key facts of GPR55
- Summary points
- References
- Chapter 30: Proteomic analysis of cannabinoids in human oligodendrocyte cells
- Abstract
- Oligodendrocytes
- Proteomics
- Endocannabinoids
- CB1 and CB2 agonists
- CB1 and CB2 antagonists
- Phytocannabinoids
- Conclusion
- Applications to other areas
- Key fact
- Mini-dictionary of terms
- Summary points
- References
- Chapter 31: Cannabinoids and endocannabinoid signaling at the basal forebrain cholinergic system
- Abstract
- Introduction: The basal forebrain cholinergic system
- Degeneration of the basal forebrain cholinergic system: Role in AD
- The endocannabinoid system in the basal forebrain cholinergic pathways
- Interaction between cholinergic and endocannabinoid systems
- Cholinergic-cannabinoid crosstalk in animal models of genetic AD
- Cholinergic-cannabinoid crosstalk in the 3xTg-AD mice model of genetic AD
- Lesion of the nucleus basalis magnocellularis: Animal models of dementia associated to cholinergic impairment
- Modulation of the eCB system in the 192IgG-saporin cholinergic lesion model
- Applications to other areas
- Mini-dictionary of terms
- Key facts of the endocannabinoid system in cognitive impairment
- Summary points
- References
- Chapter 32: Cannabidiol (the major nonpsychotropic cannabinoid in the cannabis plant) and the PI3K/AKT signaling pathway in the CNS
- Abstract
- Introduction
- PI3K/AKT signaling pathway
- PI3K/AKT signaling pathway is involved in CBD-induced neuroprotection: Evidence from animal models
- Use of in vitro models to elucidate the involvement of PI3k/AKT signaling pathway in the neuroprotective effects of Cannabidiol
- Concluding remarks
- Applications to other areas
- Mini-dictionary of terms
- Key facts
- Summary points
- References
- Chapter 33: Effects of cannabidiol and other phytocannabinoids on voltage- and ligand-gated ion channels
- Abstract
- Introduction
- Effects of cannabidiol on voltage-gated sodium channels
- Effects of cannabidiol on voltage-gated calcium channels
- Effects of cannabidiol on voltage-gated potassium channels
- Effects of cannabidiol on ligand-gated ion channels
- Effects of cannabidiol on transient receptor potential channels
- Conclusion
- Summary points
- References
- Chapter 34: Cannabis, neurodevelopment, and the “two-hit” hypothesis
- Abstract
- Introduction
- Adolescence is a sensitive developmental window
- The endocannabinoid system and the developing brain
- Mechanisms of action of cannabis
- Differential effects of THC and CBD
- Evidence for cannabis use and risk for psychosis
- The “two-hit” hypothesis
- Conclusion
- Applications to other areas
- Mini-dictionary of terms
- Key facts of cannabis and the “two-hit” hypothesis
- Summary points
- References
- Part VI: New and synthetic cannabinoids
- Chapter 35: Impact of Δ9-tetrahydrocannabinol (THC) and synthetic “spice” cannabinoids on nicotine use and abuse
- Abstract
- Tobacco and nicotine
- Cannabis, THC, and spice
- Brain mechanisms underlying drug use
- Impact of cannabinoids on cognition, behavior, and nicotine use
- Nicotine and cannabis cessation
- Applications to other areas
- Key facts
- Mini-dictionary of terms
- Summary points
- References
- Chapter 36: Synthetic cannabinoid receptor agonists compared to Δ9-tetrahydrocannabinol: Neurological effects and beyond
- Abstract
- Introduction
- Central nervous system effects
- Cardiovascular effects
- Respiratory depression
- Renal effects
- Cannabinoids in cancer treatment
- Applications to other areas
- Mini-dictionary of terms
- Key facts of THC compared to synthetic cannabinoid receptor agonists
- Summary points
- References
- Further reading
- Part VII: Biomarkers, analysis and screening
- Chapter 37: The DSM: 5 Criteria of cannabis use disorder: Methods and applications
- Abstract
- Introduction
- Inception of new DSM-5 criteria for cannabis use disorder
- DSM-5 workgroup on devising criteria for cannabis use disorder
- Concordance/compatibility of DSM-5 with DSM-IV and other classificatory systems
- Prevalence of various DSM-5 criteria for cannabis use disorder
- Assessment instruments based on DSM-5 for cannabis use disorder
- Application of current criteria
- Cannabis withdrawal syndrome: Insights and controversies
- Limitations in the current DSM-5 classification in the context of cannabis use disorder
- Future research
- Conclusion
- Applications to other areas
- Mini-dictionary of terms
- Key facts of DSM-5
- Summary points
- References
- Chapter 38: Cannabis and clinical high risk for psychosis: Monitoring and smartphones
- Abstract
- Introduction and orientation to the chapter
- General population studies on cannabis use and its impact on psychosis
- Clinical high risk for developing psychosis
- Cannabis use monitoring
- Cannabis use tracking and mobile applications
- Summary
- Applications to other areas
- Mini-dictionary of terms
- Key facts of cannabis use for those at CHR
- Summary points
- References
- Part VIII: Impact on non-neurological systems
- Chapter 39: The impact of cannabis and cannabinoids on the skin
- Abstract
- Introduction
- Cannabinoid receptors
- Non-cannabinoid receptors
- Physiologic roles of cannabinoids in the skin
- Non-melanoma skin cancer (NMSC)
- Melanoma
- Psoriasis
- Acne vulgaris and seborrhea
- Alopecia and hair growth disorders
- Pruritus
- Atopic dermatitis
- Allergic contact dermatitis
- Connective tissue disorders
- Pain
- Wound healing and skin aging
- Cutaneous adverse effects
- Conclusion
- Applications to other areas
- Mini-dictionary of terms
- Key facts of inflammation in the skin
- Summary points
- References
- Chapter 40: Cannabis consumption in reproductive function and teratogenicity
- Abstract
- Cannabis in reproduction and fertility
- Cannabis action on ontogeny
- Conclusion
- Applications to other areas
- Mini-dictionary of terms
- Key facts of cannabis in reproductive function
- Summary points
- References
- Chapter 41: Phytocannabinoids have cytotoxic, antiproliferative, and antimigratory activities on cancer cells and cancer stem cells
- Abstract
- Introduction
- Cancer stem cells
- Glioma and glioblastoma
- Cancer and the endocannabinoid system
- Anticancer activities of cannabis compounds
- The entourage effect and synergies between cannabis compounds
- Mechanism of anticancer activity of phytocannabinoids
- Effect of phytocannabinoids on normal tissue
- Summary
- Application to other areas
- Mini-dictionary of terms (alphabetical)
- Key facts about secondary metabolites
- Summary points
- References
- Part IX: Treatments and strategies
- Chapter 42: Motivational interviewing for cannabis use disorders: A narrative review from research to practice
- Abstract
- Introduction: Motivational interviewing: Definition, concepts, and key components
- The spirit
- The techniques
- Section 1: Evidence from addictions field beyond cannabis use disorders
- Section 2: Reviewing evidence of motivational interviewing for CUD
- Section 3: MI for CUD in the real world: Characteristics and case example
- Applications to other areas
- Key facts
- Mini-dictionary of terms
- Summary points
- References
- Chapter 43: An overview of current pharmacologic interventions for management of cannabis withdrawal syndrome and the evidence for their use
- Abstract
- Introduction
- CWS: An overview
- CWS treatments
- Future directions
- Conclusions
- Applications to other areas
- Key facts of GABA
- Mini-dictionary of terms
- Summary points
- References
- Chapter 44: Managing cannabinoid hyperemesis syndrome in pediatrics: A new narrative review
- Abstract
- Introduction
- Background and epidemiology
- Diagnosis
- Pathophysiology
- Antiemetic pharmacology review
- Effective, ineffective, and supportive medication therapies in CHS
- Safety considerations
- Disease states
- Mini-dictionary
- Key facts
- Summary points
- References
- Chapter 45: Gabapentinoids for the treatment of cannabis use disorder: A focus on human laboratory research
- Abstract
- Introduction
- Gabapentinoid pharmacology
- Preclinical evidence supporting gabapentinoids as CUD medications
- Clinical evaluation of gabapentinoids as CUD medications
- Separate and combined effects of gabapentin and THC in cannabis users discriminating THC: Drug discrimination rationale and design
- Separate and combined effects of gabapentin and THC in cannabis users discriminating THC: Methods
- Separate and combined effects of gabapentin and THC in cannabis users discriminating THC: Results and discussion
- Separate and combined effects of gabapentin and THC in cannabis users discriminating THC: Summary and conclusions
- Influence of pregabalin maintenance on cannabis reinforcement and related behaviors: Self-administration rationale and design
- Influence of pregabalin maintenance on cannabis reinforcement and related behaviors: Methods
- Influence of pregabalin maintenance on cannabis reinforcement and related behaviors: Results and discussion
- Influence of pregabalin maintenance on cannabis reinforcement and related behaviors: Summary and conclusion
- Final conclusions
- Applications to other areas
- Mini-dictionary of terms
- Key facts of Gabapentinoids for the treatment of cannabis use disorder: A focus on human laboratory research
- Summary points
- References
- Chapter 46: Treating psychosis in users of synthetic cannabinoids
- Abstract
- Introduction
- Psychic disorders resulting from synthetic cannabinoid use
- Psychosis duration
- Applications to other areas
- Mini-dictionary of terms
- Key facts of acute psychosis
- Summary points
- References
- Further reading
- Part X: Resources
- Chapter 47: Recommended resources for studying and investigating cannabis use, neurobiology, psychology, and treatments
- Abstract
- Acknowledgments
- Introduction
- Resources
- Other resources
- Summary points
- References
- Index
- No. of pages: 670
- Language: English
- Edition: 1
- Published: June 2, 2023
- Imprint: Academic Press
- Hardback ISBN: 9780323898621
- eBook ISBN: 9780323901406
CR
Colin R Martin
Colin R. Martin RN, BSc, MSc, PhD, MBA, YCAP, FHEA, C.Psychol, AFBPsS, C.Sci is Professor of Clinical Psychobiology and Applied Psychoneuroimmunology and Clinical Director of the Institute of Health and Wellbeing at the University of Suffolk, UK. He is a Chartered Health Psychologist and a Chartered Scientist. He also trained in analytical biochemistry, this aspect reflecting the psychobiological focus of much of his research within mental health. He has published or has in press well over 300 research papers and book chapters. He is a keen book author and editor having written and/or edited more than 50 books. These outputs include the prophetic insight into the treatment of neurological disease, Handbook of Behavior, Food and Nutrition (2011), Nanomedicine and the Nervous System (2012), Oxidative Stress and Dietary Antioxidants in Neurological Disease (2020), Zika Virus Impact, Diagnosis, Control and Models (2021), Factors Affecting Neurodevelopment: Genetics, Neurology, Behavior and Diet (2021), Diagnosis and Treatment of Spinal Cord Injury (2022), The Neurobiology, Physiology, and Psychology of Pain (2022) and The Handbook of Lifespan Cognitive Behavioral Therapy: Childhood, Adolescence, Pregnancy, Adulthood, and Aging (2023). Professor Martin is particularly interested in all aspects of the relationship between underlying physiological substrates and behavior, particularly in how these relationships manifest in both acute and chronic psychiatric disorder. He has published original research germane to significant mental health disorders including the areas of schizophrenia, anxiety, depression, self-esteem, alcohol and drug dependency, high secure forensic mental health and personality disorder. He has a keen interest in the impact of postviral illness and is actively involved in clinical research post-Covid pandemic and in particular, the impact of Long Covid on psychological, neurological, physiological and social functioning. He is involved in collaborative International research with many European and Non-European countries.
Affiliations and expertise
Professor of Clinical Psychobiology and Applied Psychoneuroimmunology and Clinical Director: Institute for Health and Wellbeing, University of Suffolk, Ipswich, UKVP
Vinood B. Patel
Dr. Patel is a Reader at the University of Westminster. After completing his PhD at King’s College London, he continued his research experience by undertaking his post-doctoral studies in the laboratory of Professor Cunningham in the Department of Biochemistry at the Wake Forest University School of Medicine, (Winston-Salem, NC, USA). This extensive project involved investigating mechanisms of hepatic mitochondrial ribosome dysfunction in alcoholic liver disease (ALD) using biophysical and proteomic techniques. These studies have led to new avenues in determining the pathology of ALD. His teaching areas at both post-graduate and undergraduate levels include clinical biochemistry, investigative pathology and laboratory investigation.
Affiliations and expertise
Reader, University of Westminster, London, UKVP
Victor R Preedy
Victor R. Preedy BSc, PhD, DSc, FRSB, FRSPH, FRSC, FRCPath graduated with an Honours Degree in Biology and Physiology with Pharmacology. After gaining his University of London PhD, he received his Membership of the Royal College of Pathologists. He was later awarded his second doctorate (DSc), for his contribution to protein metabolism in health and disease. He is Professor of Clinical Biochemistry (Hon) at King’s College Hospital and Emeritus Professor of Nutritional Biochemistry at King’s College London. He has Honorary Professorships at the University of Hull, and the University of Suffolk. Professor Preedy was the Founding Director and then long-term Director of the Genomics Centre at King’s College London from 2006 to 2020. Professor Preedy has been awarded fellowships of the Royal Society of Biology, the Royal College of Pathologists, the Royal Society for the Promotion of Health, the Royal Institute of Public Health, the Royal Society for Public Health, the Royal Society of Chemistry and the Royal Society of Medicine. He carried out research when attached to the National Heart Hospital (part of Imperial College London), The School of Pharmacy (now part of University College London) and the MRC Centre at Northwick Park Hospital. He has collaborated with international research groups in Finland, Japan, Australia, USA, and Germany. To his credit, Professor Preedy has published over 750 articles, which includes peer-reviewed manuscripts based on original research, abstracts and symposium presentations, reviews and edited books.
Affiliations and expertise
Professor, Department of Clinical Biochemistry, King’s College Hospital, London, UK; Emeritus Professor, Faculty of Life Sciences and Medicine, King’s College London, UK Visiting Professor, University of Hull, UKRead Cannabis Use, Neurobiology, Psychology, and Treatment on ScienceDirect